ITD 1 |
| Katalog-Nr.GC12108 |
ITD 1 ist der erste selektive TGFβ-Rezeptor-Inhibitor mit einem IC50 von 460 nM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1099644-42-4
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
ITD 1 is a selective TGFβ receptor inhibitor (IC50 = 460nM) [1]. ITD 1 promotes the differentiation of stem cells into cardiomyocytes by inhibiting the Wnt/β-catenin signaling pathway [2]. ITD 1 is used in basic research such as cardiac regeneration [3-4].
In U87 and U251 cells, cell proliferation was inhibited after ITD 1 (5μM; 24h) treatment [5]. In human fibroblasts, inhibition of TβRII by ITD 1 (5μM; 24h) under hypoxic conditions reduces p-Smad2/3 levels and collagen deposition [6]. In human corneal endothelial cells, ITD 1 (10μM; 48h) inhibits cell proliferation, accelerates senescence, and reduces the expression of endothelial cell markers [7].
In C57BL/6J mice, ITD 1 (20μL; 2000ng; im; 4d) reduced TGF-β activity in muscle [8]. In Lewis cell subcutaneous tumor mouse model, ITD 1 (5mg/kg; ip; 5d) weakened SAHA-induced anti-tumor immunity and CD8+ T cell activation by inhibiting Smad2/3 signaling [9].
References:
[1]. Willems E, Cabral-Teixeira J, Schade D, et al. Small molecule-mediated TGF-β type II receptor degradation promotes cardiomyogenesis in embryonic stem cells[J]. Cell stem cell, 2012, 11(2): 242-252.
[2]. Zhong Q, Laco F, Liao M C, et al. Influencing the fate of cardiac and neural stem cell differentiation using small molecule inhibitors of alk5[J]. Stem cells translational medicine, 2018, 7(10): 709-720.
[3]. Plowright A T, Engkvist O, Gill A, et al. Heart regeneration: opportunities and challenges for drug discovery with novel chemical and therapeutic methods or agents[J]. Angewandte Chemie International Edition, 2014, 53(16): 4056-4075.
[4]. Lin Y H, Kang L, Feng W H, et al. Effects of lipids and lipoproteins on mesenchymal stem cells used in cardiac tissue regeneration[J]. International journal of molecular sciences, 2020, 21(13): 4770.
[5]. Sun Z, Yan T, Jiang H, et al. Claudin-3 facilitates the progression and mediates the tumorigenic effects of TGF-β in glioblastoma multiforme[J]. Medical Oncology, 2023, 40(9): 268.
[6]. Mingyuan X, Qianqian P, Shengquan X, et al. Hypoxia-inducible factor-1α activates transforming growth factor-β1/Smad signaling and increases collagen deposition in dermal fibroblasts[J]. Oncotarget, 2017, 9(3): 3188.
[7]. Ozen E A, Toprak E K, Donmez A Ç, et al. Investigation of the Effects of TGF-β and TGF-β Inhibitors on Cell Proliferation and Senescence in Human Corneal Endothelial Cells[J]. Acta Physiologica, 2023, 237.
[8]. Mázala D A G, Novak J S, Hogarth M W, et al. TGF-β–driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse model[J]. Jci Insight, 2020, 5(6): e135703.
[9]. Dong W, He B, Cao Y, et al. Low-dose SAHA enhances CD8+ T cell-mediated antitumor immunity by boosting MHC I expression in non-small cell lung cancer[J]. Cellular Oncology, 2025, 48(1): 249-264.
| Cell experiment [1]: | |
Cell lines | U87 and U251 cells |
Preparation Method | U87 and U251 cells were seeded at a density of 5,000 cells per well in 96-well plates and incubated at 37℃ for 24 hours before being treated with DMSO, TGF-β1 (10ng/mL), or ITD 1 (5μM). Following treatment, 10μL of CCK-8 reagent was added to each well and incubated for 24h. Cell viability was then assessed. |
Reaction Conditions | 5μM; 24h |
Applications | After ITD 1 treatment, cell proliferation was inhibited. |
| Animal experiment [2]: | |
Animal models | C57BL/6J mice |
Preparation Method | 24-day-old mice were anesthetized with isoflurane and shaved from the anterior hind limbs. Then, 40μL of NTX (10μg/mL) was injected into the tibialis anterior (TA) muscle using a 28-gauge insulin syringe. The needle was first dipped in green tattoo dye to mark the injury site. For the ITD 1 treatment group, 2000 ng of ITD 1 was added to 30μL of NTX (10μg/mL) and injected into one TA muscle, while the contralateral TA muscle received only 30μL of NTX. On days 2 and 4 after the initial injection, 20μL of ITD 1 (2000ng) was injected into the TA muscle of the ITD 1-injected side, and the contralateral TA muscle received an equal volume of saline. |
Dosage form | 20μL; 2000ng; im; 4d |
Applications | ITD 1 reduced TGF-β activity in muscle. |
References: | |
| Cas No. | 1099644-42-4 | SDF | |
| Chemical Name | (Z)-1-(5-(tert-butyl)isoxazol-3(2H)-ylidene)-3-(4-(7-(2-morpholinoethoxy)benzo[d]imidazo[2,1-b]thiazol-2-yl)phenyl)urea | ||
| Canonical SMILES | CC(C)(C1=C/C(NO1)=N/C(NC2=CC=C(C3=CN(C4=N3)C5=C(S4)C=C(OCCN6CCOCC6)C=C5)C=C2)=O)C | ||
| Formula | C29H32N6O4S | M.Wt | 560.67 |
| Löslichkeit | ≥ 28.05mg/mL in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.7836 mL | 8.9179 mL | 17.8358 mL |
| 5 mM | 356.7 μL | 1.7836 mL | 3.5672 mL |
| 10 mM | 178.4 μL | 891.8 μL | 1.7836 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 38 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *